The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
NeoOPTIMIZE: An open-label, phase II trial and biomarker discovery platform to assess the efficacy of adaptive switching of modified FOLFIRINOX (mFFX) or gemcitabine/nab-paclitaxel (GA) as a neoadjuvant strategy for patients with resectable/borderline resectable and locally advanced unresectable pancreatic ductal adenocarcinoma (PDAC).
 
Charles D. Lopez
Consulting or Advisory Role - Astellas Pharma; Exelixis; Pfizer
Research Funding - Taiho Pharmaceutical
Travel, Accommodations, Expenses - RenovoRx
 
Adel Kardosh
Consulting or Advisory Role - Astellas Pharma; Eisai; Eisai; Exelixis; Exelixis
 
Emerson Yu-sheng Chen
No Relationships to Disclose
 
Skye C. Mayo
No Relationships to Disclose
 
Robert Eil
Consulting or Advisory Role - Lyell Immunopharma
Patents, Royalties, Other Intellectual Property - NIH/NCI (Inst)
 
Patrick Joseph Worth
No Relationships to Disclose
 
Erin W. Gilbert
No Relationships to Disclose
 
Flavio G. Rocha
Consulting or Advisory Role - Medtronic
Research Funding - Gunze
 
Nima Nabavizadeh
No Relationships to Disclose
 
Aaron Grossberg
No Relationships to Disclose
 
Alexander Guimaraes
Consulting or Advisory Role - Merck; Pfizer
 
Bryan Foster
Consulting or Advisory Role - Bot Image
 
Brian Brinkerhoff
No Relationships to Disclose
 
Shaun Goodyear
Consulting or Advisory Role - PDX Pharmacy
 
Erin Taber
No Relationships to Disclose
 
Dove Keith
No Relationships to Disclose
 
Jonathan Robert Brody
No Relationships to Disclose
 
Gordon B. Mills
Stock and Other Ownership Interests - Amphista Therapeutics; AstraZeneca; Catena; Chrysalis Biotherapeutics; Genentech; GlaxoSmithKline; ImmunoMET; Ionis Pharmaceuticals; Myriad Genetics; NanoString Technologies; PDX Pharmacy; SignalChem; Symphogen; Tarveda Therapeutics; Turbine; Zentalis
Honoraria - Amphista Therapeutics; AstraZeneca; Chrysalis Biotherapeutics; GlaxoSmithKline; ImmunoMET; Lilly; PDX Pharmacy; SignalChem; Symphogen; Tarveda Therapeutics; Turbine; Zentalis
Consulting or Advisory Role - Amphista Therapeutics; AstraZeneca; Chrysalis Biotherapeutics; GlaxoSmithKline; ImmunoMET; Ionis Pharmaceuticals; Lilly; PDX Pharmacy; SignalChem
Research Funding - Amphista Therapeutics; AstraZeneca; Catena; Chrysalis Biotherapeutics; GlaxoSmithKline; ImmunoMET; Ionis Pharmaceuticals; Lilly; PDX Pharmacy; SignalChem; Symphogen; Tarveda Therapeutics; Turbine; Zentalis
Patents, Royalties, Other Intellectual Property - Amphista Therapeutics; AstraZeneca; Catena; Chrysalis biotherapeutics; Genentech; GlaxoSmithKline; ImmunoMET; Ionis Pharmaceuticals; Lilly; Myriad Genetics; NanoString Technologies; PDX Pharmacy; SignalChem; Symphogen; Tarveda Therapeutics; Turbine; Zentalis
Travel, Accommodations, Expenses - Amphista Therapeutics; AstraZeneca; Catena; Chrysalis Biotherapeutics; Genentech; GlaxoSmithKline; ImmunoMET; Ionis Pharmaceuticals; Lilly; Myriad Genetics; NanoString Technologies; PDX Pharmacy; SignalChem; Symphogen; Tarveda Therapeutics; Turbine; Zentalis
Other Relationship - Amphista Therapeutics; AstraZeneca; Catena; Chrysalis Biotherapeutics; Genentech; GlaxoSmithKline Canada; ImmunoMET; Ionis Pharmaceuticals; Lilly; Myriad Genetics; NanoString Technologies; PDX Pharmacy; SignalChem; Symphogen; Tarveda Therapeutics; Turbine; Zentalis
 
Rosalie Sears
Consulting or Advisory Role - Novartis; Rappta Therapeutics
Travel, Accommodations, Expenses - Rappta Therapeutics
 
Brett C. Sheppard
No Relationships to Disclose